

## **JOURNAL OF BONE ONCOLOGY**

AUTHOR INFORMATION PACK

ISSN: 2212-1374

## **TABLE OF CONTENTS**

| • | Description              | p.1 |  |
|---|--------------------------|-----|--|
| • | Abstracting and Indexing | p.1 |  |
| • | <b>Editorial Board</b>   | p.1 |  |
| • | Guide for Authors        | p.4 |  |

#### DESCRIPTION

The *Journal of Bone Oncology* is a peer-reviewed international journal aimed at presenting basic, translational and clinical high-quality research related to **bone** and **cancer**.

As the first journal dedicated to **cancer induced bone diseases**, *JBO* welcomes original research articles, review articles, editorials and opinion pieces. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject. The areas covered by the journal include: **Bone metastases** (pathophysiology, epidemiology, diagnostics, clinical features, prevention, treatment)Preclinical models of **metastasisBone** microenvironment in **cancer** (stem cell, bone cell and cancer interactions)**Bone** targeted therapy (pharmacology, therapeutic targets, drug development, clinical trials, side-effects, outcome research, health economics)**Cancer** treatment induced **bone** loss (epidemiology, pathophysiology, prevention and management)**Bone** imaging (clinical and animal, skeletal interventional radiology)**Bone** biomarkers (clinical and translational applications)Radiotherapy and radio-isotopesSkeletal complications**Bone** pain (mechanisms and management)**Orthopaedic cancer** surgeryPrimary **bone tumours**Clinical **guidelinesMultidisciplinary** care

Keywords: bisphosphonate, bone, breast cancer, cancer, CTIBL, denosumab, metastasis, myeloma, osteoblast, osteoclast, osteooncology, osteo-oncology, prostate cancer, skeleton, tumour

## ABSTRACTING AND INDEXING

Scopus

## **EDITORIAL BOARD**

#### Editors-in-Chief:

**Robert Coleman**, Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, S10 2SJ, UK **Peyman Hadji**, Krankenhaus Nordwest, Klinik für Gyn ä kologie und Geburtshilfe, Sektion Osteoonkologie, Gynäkologische Endokrinologie und Reproduktionsmedizin, Steinbacher Hohl 2-26, 60488 Frankfurt am Main, Germany

## Editorial Board:

Richard Bell, The Andrew Love Cancer Centre
The Geelong Hospital and Deakin University
70 Swanston Street
Geelong 3250, Australia
Jean-Jacques Body, University Hospital Brugmann
Department of Medicine
Université Libre de Bruxelles

Brussels 1020, Belgium

Richard De Boer, Department of Medical Oncology

Royal Melbourne Hospital

Parkville, 3050, Melbourne, Australia

Brendan F. Boyce, Department of Pathology and Laboratory Medicine

University of Rochester Medical Center

Rochester, NY 14534, US

**Adam Brufsky**, University of Pittsburgh

Pittsburgh, PA 15213, US

Øyvind Bruland, University of Oslo

The Norwegian Radium Hospital

Montebello

N-0310 Oslo, Norway

Edward Chow, Department of Radiation Oncology

University of Toronto

Sunnybrook Health Sciences Centre

Odette Cancer Centre

2075 Bayview Avenue

Toronto ON M4N 3M5, Canada

Mark Clemons, Division of Medical Oncology

The Ottawa Hospital Cancer Centre (Box 912)

501 Smyth Road

Ottawa ON K1H 8L6, Canada

Luis Costa, Servico de Oncologia

Hospital Santa Maria, EPE

Av. Prof. Egas Moniz

1649-035 Lisboa, Portugal

Ingo Diel, SPGO

Quadrat P7, 16-17

D-68161 Mannheim, Germany

Michael Gnant, Department of Surgery and Comprehensive Cancer Center

Medical University of Vienna

Waehringer Guertel 18-20

A-1090 Vienna, Austria

Julie Gralow, University of Washington

Seattle Cancer Care Alliance

825 Eastlake Avenue East G3-630

Seattle, WA 98109, US

Dominique Heymann, University of Nantes

INSERM UMR957

Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumors

44035 Nantes, France

Lorenz Hofbauer, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

Anstalt des öffentlichen Rechts des Freistaates Sachsen

Fetscherstraße 74, 01307 Dresden, Germany

Ingunn Holen, Academic Unit of Clinical Oncology

GU24

Medical School

University of Sheffield

Beech Hill Road

Sheffield S10 2RX, UK

Peter J. Hoskin, Mount Vernon Cancer Centre

Northwood

Middlesex, UK

Norio Kohno, Department of Breast Oncology

Tokyo Medical University

Shinjuku, Tokyo, Japan

Andreas A. Kurth, Weidmannstr. 61

55131 Mainz, Germany

**Allan Lipton**, MS Hershey Medical Center of the Pennsylvania State University Hershey, PA 17033, US

**Toshio Matsumoto**, Department of Medicine and Bioregulatory Sciences University of Tokushima Graduate School of Medical Sciences

Tokushima, 770-8503, Japan

Gabri van der Pluijm, Department of Urology

Leiden University Medical Center

Albinusdreef 2, 2333 ZA Leiden

The Netherlands

**David Roodman**, Indiana University, Joseph E. Walther Hall, Room C312c, 980 W. Walnut St., Indianapolis, IN 46202, USA

Daniele Santini, Medical Oncology Department

University Campus Bio-Medico Via Alvaro del Portillo, 200

00128 Rome, Italy

Markus J. Seibel, Professor of Endocrinology

The University of Sydney

Director, Dept of Endocrinology & Metabolism,

Condord Repatriation General Hospital

Director, Bone Research Program

ANZAC Research Institute

Concord, NSW 2139, Australia

Matt Smith, Massachusetts General Hospital Cancer Center

Harvard Medical School

Boston, Massachusetts, US

Toshiyuki Yoneda, Indiana University School of Medicine

Division of Hematology/Oncology

Walther Hall R3-C321D, 980 W Walnut St

Indianapolis, IN 46202, US

## **GUIDE FOR AUTHORS**

## **INTRODUCTION**

## Types of article

Submissions covering the research areas mentioned under the section "Aims & Scope" are welcome for publication.

Journal of Bone Oncology focuses primarily on original research articles and reviews. Case reports will only be considered in exceptional circumstances and only when accompanied by a comprehensive review of the subject.

#### **BEFORE YOU BEGIN**

## Ethics in publishing

**Please note**: Before completing the online submission, authors will have to confirm that their submission is in conformity with the Elsevier Guidelines for Ethics in Publishing, see <a href="http://www.elsevier.com/publishingethics">http://www.elsevier.com/publishingethics</a> and <a href="http://www.elsevier.com/ethicalguidelines">http://www.elsevier.com/publishingethics</a> and <a href="http://www.elsevier.com/ethicalguidelines">http://www.elsevier.com/publishingethics</a> and <a href="http://www.elsevier.com/ethicalguidelines">http://www.elsevier.com/ethicalguidelines</a>.

## Conflict of interest

All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also <a href="http://www.elsevier.com/conflictsofinterest">http://www.elsevier.com/conflictsofinterest</a>. Further information and an example of a Conflict of Interest form can be found at: <a href="http://help.elsevier.com/app/answers/detail/a\_id/286/p/7923">http://help.elsevier.com/app/answers/detail/a\_id/286/p/7923</a>.

JBO requires full disclosure of all potential conflicts of interest. All sources of funding supporting the work are to be declared. At the end of the manuscript text (and in the cover letter of the manuscript), under a subheading "Conflict of Interest statement", all authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. If there are no conflicts of interest, the authors should state, "The authors declare that there are no conflicts of interest." Signed copies of the JBO Conflict of Interest policy form are required upon submission. The Conflict of Interest policy form can be downloaded here. In order to minimize delays, we strongly advise that the signed copies of these statements are prepared before you submit your manuscript. The corresponding author is responsible for sharing this document with all coauthors. Each and every co-author must sign an individual disclosure form. The corresponding author is responsible for uploading their form and those of their co-authors.

#### Informed consent

Identifying information, including patients' names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Images of patients or volunteers should not be used unless the information is essential for scientific purposes and explicit permission has been given as part of the consent. When informed consent has been obtained it should be indicated in the published article.

## Human and animal rights

Studies on humans or animals require local organizational ethics committee approval. When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body (ethics committee) explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should be asked to indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

## Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis or as an electronic preprint, see <a href="http://www.elsevier.com/postingpolicy">http://www.elsevier.com/postingpolicy</a>), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere

in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service CrossCheck <a href="http://www.elsevier.com/editors/plagdetect">http://www.elsevier.com/editors/plagdetect</a>.

## Authorship

All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.

## Changes to authorship

This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

Before the accepted manuscript is published in an online issue: Requests to add or remove an author, or to rearrange the author names, must be sent to the Journal Manager from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Journal Manager to the corresponding author, who must follow the procedure as described above. Note that: (1) Journal Managers will inform the Journal Editors of any such requests and (2) publication of the accepted manuscript in an online issue is suspended until authorship has been agreed.

After the accepted manuscript is published in an online issue: Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above and result in a corrigendum.

#### Biomarkers

Submissions which report biomarkers must comply with the REMARK Guidelines (McShane L, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK), Eur J Cancer, 2005, 41, 1690–1696.)

## Registration of clinical trial results

Please see the recommendations as given by the International Committee of Medical Journal Editors concerning the registration of clinical trial results (http://www.icmje.org/publishing\_10register.html and http://www.icmje.org/fag\_clinical.html).

#### Copyright

This journal offers authors a choice in publishing their research: Open access and Subscription.

## For subscription articles

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see <a href="http://www.elsevier.com/copyright">http://www.elsevier.com/copyright</a>). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations (please consult <a href="http://www.elsevier.com/permissions">http://www.elsevier.com/permissions</a>). If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms for use by authors in these cases: please consult <a href="http://www.elsevier.com/permissions">http://www.elsevier.com/permissions</a>.

#### For open access articles

Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (for more information see <a href="http://www.elsevier.com/OAauthoragreement">http://www.elsevier.com/OAauthoragreement</a>). Permitted reuse of open access articles is determined by the author's choice of user license (see <a href="http://www.elsevier.com/openaccesslicenses">http://www.elsevier.com/openaccesslicenses</a>).

## Retained author rights

As an author you (or your employer or institution) retain certain rights. For more information on author rights for:

Subscription articles please see

http://www.elsevier.com/journal-authors/author-rights-and-responsibilities.

Open access articles please see http://www.elsevier.com/OAauthoragreement.

## Role of the funding source

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

## Funding body agreements and policies

Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <a href="http://www.elsevier.com/fundingbodies">http://www.elsevier.com/fundingbodies</a>.

## Open access

This journal offers authors a choice in publishing their research:

## Open access

- Articles are freely available to both subscribers and the wider public with permitted reuse
- An open access publication fee is payable by authors or their research funder

## Subscription

- Articles are made available to subscribers as well as developing countries and patient groups through our access programs (http://www.elsevier.com/access)
- No open access publication fee

All articles published open access will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by your choice of one of the following Creative Commons user licenses:

**Creative Commons Attribution (CC BY)**: lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

**Creative Commons Attribution-NonCommercial-ShareAlike (CC BY-NC-SA)**: for noncommercial purposes, lets others distribute and copy the article, to create extracts, abstracts and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text and data mine the article, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, do not modify the article in such a way as to damage the author's honor or reputation, and license their new adaptations or creations under identical terms (CC BY-NC-SA).

**Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)**: for noncommercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

To provide open access, this journal has a publication fee which needs to be met by the authors or their research funders for each article published open access.

Your publication choice will have no effect on the peer review process or acceptance of submitted articles.

The publication fee for this journal is **\$1700**, excluding taxes. Learn more about Elsevier's pricing policy: <a href="http://www.elsevier.com/openaccesspricing">http://www.elsevier.com/openaccesspricing</a>.

## Language (usage and editing services)

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop (http://webshop.elsevier.com/languageediting/) or visit our customer support site (http://support.elsevier.com) for more information.

## Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author and copies of the consents or evidence that such consents have been obtained must be provided to Elsevier on request. For more information, please review the *Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals*, <a href="http://www.elsevier.com/patient-consent-policy">http://www.elsevier.com/patient-consent-policy</a>. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

#### Submission

Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.

### Submit your article

Please submit your article viahttp://www.evise.com/evise/faces/pages/navigation/NavController.jspx?JRNL ACR=JBO.

#### Referees

Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

## **PREPARATION**

## Use of word processing software

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: <a href="http://www.elsevier.com/guidepublication">http://www.elsevier.com/guidepublication</a>). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

## **Article structure**

Subdivision - unnumbered sections

Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

#### Introduction

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### Material and methods

Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.

## Theory/calculation

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

#### Results

Results should be clear and concise.

#### Discussion

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

#### Conclusions

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

## **Appendices**

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

## Essential title page information

- *Title.* Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that phone numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address. Contact details must be kept up to date by the corresponding author.
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

#### Ahstract

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

#### Graphical abstract

A Graphical abstract is optional and should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article. Graphical abstracts should be submitted as a separate file in the online submission system. Image size: Please provide an image with a minimum of  $531 \times 1328$  pixels (h × w) or proportionally more. The image should be readable at a size of  $5 \times 13$  cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. See http://www.elsevier.com/graphicalabstracts for examples.

Authors can make use of Elsevier's Illustration and Enhancement service to ensure the best presentation of their images also in accordance with all technical requirements: Illustration Service.

## **Highlights**

Highlights are a short collection of bullet points that convey the core findings of the article. Highlights are optional and should be submitted in a separate file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). See <a href="http://www.elsevier.com/highlights">http://www.elsevier.com/highlights</a> for examples.

## Keywords

Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### **Abbreviations**

Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

## **Acknowledgements**

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### Units

Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

## Database linking

Elsevier encourages authors to connect articles with external databases, giving their readers oneclick access to relevant databases that help to build a better understanding of the described research. Please refer to relevant database identifiers using the following format in your article: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN). See http://www.elsevier.com/databaselinking for more information and a full list of supported databases.

## Math formulae

Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

#### **Footnotes**

Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

#### Table footnotes

Indicate each footnote in a table with a superscript lowercase letter.

#### **Artwork**

#### Image manipulation

Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

#### Electronic artwork

## General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.

- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the printed version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available on our website:

http://www.elsevier.com/artworkinstructions

# You are urged to visit this site; some excerpts from the detailed information are given here. Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi. TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

#### Please do not:

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

#### Color artwork

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article. Please indicate your preference for color: in print or on the Web only. For further information on the preparation of electronic artwork, please see <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>.

Please note: Because of technical complications which can arise by converting color figures to 'gray scale' (for the printed version should you not opt for color in print) please submit in addition usable black and white versions of all the color illustrations.

#### Figure captions

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.

## References

#### Citation in text

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

#### Web references

As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

## References in a special issue

Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

#### Reference style

*Text:* Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.

List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.

## Examples:

Reference to a journal publication:

[1] Van der Geer J, Hanraads JAJ, Lupton RA. The art of writing a scientific article. J Sci Commun 2010;163:51–9.

Reference to a book:

[2] Strunk Jr W, White EB. The elements of style. 4th ed. New York: Longman; 2000.

Reference to a chapter in an edited book:

[3] Mettam GR, Adams LB. How to prepare an electronic version of your article. In: Jones BS, Smith RZ, editors. Introduction to the electronic age, New York: E-Publishing Inc; 2009, p. 281–304. Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also http://www.nlm.nih.gov/bsd/uniform\_requirements.html).

#### Journal abbreviations source

Journal names should be abbreviated according to the List of Title Word Abbreviations: http://www.issn.org/services/online-services/access-to-the-ltwa/.

## Video data

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 50 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: <a href="http://www.sciencedirect.com">http://www.sciencedirect.com</a>. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

#### **AudioSlides**

The journal encourages authors to create an AudioSlides presentation with their published article. AudioSlides are brief, webinar-style presentations that are shown next to the online article on ScienceDirect. This gives authors the opportunity to summarize their research in their own words and to help readers understand what the paper is about. More information and examples are available at <a href="http://www.elsevier.com/audioslides">http://www.elsevier.com/audioslides</a>. Authors of this journal will automatically receive an invitation e-mail to create an AudioSlides presentation after acceptance of their paper.

## Supplementary data

Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including

ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.

## Data deposit and linking

Elsevier encourages authors to deposit raw data sets underpinning their research publication in data repositories, and to enable interlinking of articles and data. Please visit <a href="http://www.elsevier.com/databaselinking">http://www.elsevier.com/databaselinking</a> for more information on depositing and linking your data with a supported data repository.

## Submission checklist

The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

## **Ensure that the following items are present:**

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address
- Phone numbers

All necessary files have been uploaded, and contain:

- Keywords
- All figure captions
- All tables (including title, description, footnotes)

Further considerations

- Manuscript has been 'spell-checked' and 'grammar-checked'
- References are in the correct format for this journal
- All references mentioned in the Reference list are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Web)
- Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print
- If only color on the Web is required, black-and-white versions of the figures are also supplied for printing purposes

For any further information please visit our customer support site at http://support.elsevier.com.

#### **AFTER ACCEPTANCE**

## Use of the Digital Object Identifier

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the journal *Physics Letters B*):

http://dx.doi.org/10.1016/j.physletb.2010.09.059

When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to change.

#### Online proof correction

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately - please upload all of your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

## **Offprints**

The corresponding author, at no cost, will be provided with a personalized link providing 50 days free access to the final published version of the article on ScienceDirect. This link can also be used for sharing via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints). Authors requiring printed copies of multiple articles may use Elsevier WebShop's 'Create Your Own Book' service to collate multiple articles within a single cover (http://webshop.elsevier.com/myarticleservices/booklets).

## **AUTHOR INQUIRIES**

For inquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage. For detailed instructions on the preparation of electronic artwork, please visit <a href="http://www.elsevier.com/artworkinstructions">http://www.elsevier.com/artworkinstructions</a>. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at <a href="http://www.elsevier.com/trackarticle">http://www.elsevier.com/trackarticle</a>. You can also check our Author FAQs at <a href="http://www.elsevier.com/authorFAQ">http://www.elsevier.com/authorFAQ</a> and/or contact Customer Support via <a href="http://support.elsevier.com">http://support.elsevier.com</a>.

© Copyright 2014 Elsevier | http://www.elsevier.com